Emedgene

Emedgene specializes in automating genomic insights to enhance data operations for hereditary disease research. Their variant interpretation software optimizes tertiary analysis workflows, particularly for rare disease genomics and germline research.

The software is designed to accelerate variant interpretation, prioritization, curation, and report generation from sequencing and microarrays. It supports genomes, exomes, virtual panels, targeted panels, and microarrays, enabling efficient analysis from individual samples to population-scale studies.

Emedgene integrates with DRAGEN secondary analysis for accurate variant calling, speeding up user-driven interpretation by up to 75%. The platform supports a wide range of variant types, including SNVs, indels, STRs, CNVs, and mtDNA, and unifies insights from cytogenetic microarrays.

Key features include:

• Explainable AI (XAI) for transparent logic and bias detection.
• Automated ACMG classifications for various variant types.
• Integration with lab digital ecosystems for seamless workflows.
• Collaboration tools for knowledge sharing across private lab networks.

Emedgene's platform is suitable for various applications, including rare and genetic disease research, hereditary risk assessment, carrier screening, and pharmacogenomics. It supports high-throughput workflows for WGS, WES, virtual panels, and microarrays.

The company emphasizes security and privacy, ensuring compliance with certifications to protect sensitive NGS data. Their AI models demonstrate 97% accuracy in prioritizing relevant insights, significantly reducing manual review time.

Emedgene also offers resources like customer use cases and research studies, showcasing the effectiveness of their machine learning technologies in eliminating genomic data interpretation bottlenecks.